Everything below concerns LC-MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-19. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | Designed to engage three receptor targets |
| Appearance | White to off-white powder | Lyophilized form supplied in sealed vials |
| Solubility | Soluble in water | Dissolves in aqueous buffer systems |
| Storage, solid | -20 °C or below | Desiccated and protected from light |
| Typical analysis | RP-HPLC with mass detection | Purity by peak area, identity by mass |
As a peptide, the compound is generally supplied as a lyophilized powder and stored frozen to slow degradation. Recommended conditions usually sit at minus twenty degrees Celsius or colder, shielded from light and moisture. Solutions are less stable than the dry powder and are often prepared fresh before analysis. Repeated freeze-thaw cycles can drive aggregation, so splitting stock material into small aliquots reduces handling stress and preserves sample integrity.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Finally, when the pressure within the ventricles falls below the pressure within the aorta and pulmonary arteries, the aortic and pulmonary valves close. The ventricles start to relax, the mitral and tricuspid valves open, and the cycle begins again.
== Overview == A sample large-scale phosphoproteomic analysis includes cultured cells undergo SILAC encoding; cells are stimulated with factor of interest (e.g. growth factor, hormone); stimulation can occur for various lengths of time for temporal analysis, cells are lysed and enzymatically digested, peptides are separated using ion exchange chromatography; phosphopeptides are enriched using phosphospecific antibodies, immobilized metal affinity chromatography or titanium dioxide (TiO2) chromatography; phosphopeptides are analyzed using mass spectrometry, and peptides are sequenced and analyzed.
He raised approximately $850,000 by February, enough money to fund the somatostatin research projects. By August 1977, the research teams managed to create the first bacterium capable of synthesizing somatostatin. This was the proof of concept that the fledgling company sought. On December 2, 1977, Swanson and the scientists held a press conference announcing their findings. Following their success with the proof of concept, Swanson then directed the scientists to pursue the creation of a bacterium that synthesized human insulin. Two other scientific teams were already attempting to carry out such a project, but Swanson moved quickly to ensure that they synthesized it first. By early 1978, his priorities were to obtain a lab space for the scientists, corporate contracts, and more funding for Genentech. In order to attract the best scientists, Swanson, with the assistance of Boyer, tried to create an attractive environment for academic scientists. It was because of this that scientists at Genentech were allowed to publish their findings in scientific journals. The restriction was that they could publish only after the appropriate patents had already been filed. By February 1978, Swanson leased a 10,000-square-foot section of an airfreight warehouse, which would serve as Genentech's first lab space. Later that year, Swanson also secured a partnership with Eli Lilly; Genentech would receive $50,000 a month to pursue the human insulin project.
=== Discontinued === Acebilustat (CTX-4430; EP-501) – leukotriene A4 (LTA4H) hydrolase inhibitor Afamelanotide (CUV-1647; EPT-1647; Melanotan I; Melanotan; Prenumbra; Scenesse) – melanocortin receptor agonist BBI-3000 – retinoid X receptor agonist BMX-010 (MnTE-2-PyP) – reactive oxygen species (ROS) scavenger and radioprotector Botulinum toxin A liquid (AI-09) – acetylcholine release inhibitor and neuromuscular blocking agent Botulinum toxin A topical (ANT-1207) – acetylcholine release inhibitor and neuromuscular blocking agent Cioteronel (CPC-10997; Cyoctol; X-Andron) – antiandrogen (androgen receptor antagonist) Diroleuton (DGLA; DHLA; DS-107; RO-12-1989) – omega-6 fatty acid and anti-inflammatory DMVT-503 (RVT-503) – undefined mechanism of action DX-0385 – retinoic acid metabolism modulator Encapsulated tretinoin cream – retinoid (retinoic acid receptor agonist) Epristeride (Aipuliete; ONO-9302; SKF-105657) – 5α-reductase inhibitor Falecalcitriol (DSC-103; F6VD3; flocalcitriol; Fulstan; hexafluorocalcitriol; hexafluorovitamin D3; Hornel; SM-8000; ST-630) – vitamin D/calcitriol analogue Gevokizumab (S-78989; VPM-087; XMA-005.2) – monoclonal antibody against interleukin-1β Hypochlorous acid (PR-013; PR-022) – disinfectant and other actions Imsidolimab (ANB-019) – monoclonal antibody against the interleukin-36 receptor Incyclinide (chemically modified tetracycline 3; CMT-3; COL-3; Metastat) – chemically modified tetracycline and matrix metalloproteinase inhibitor (no antibiotic activity) Ingenol disoxate (LEO-43204) – undefined mechanism of action JNJ-10229570 – melanocortin MC5 receptor antagonist MDI-301 – undefined mechanism of action MK-434 (MK-0434) – 5α-reductase inhibitor MTCH-24 (Zilex; Zorex) – undefined mechanism of action PF-06423264 – acetyl-CoA carboxylase inhibitor PSK-3841 (HMR-3841; RU-58841) – antiandrogen (androgen receptor antagonist) Research programme: acne therapeutics - Praxis – undefined mechanism of action Research programme: tetracycline derivatives - Paratek Pharmaceuticals (P-004292) – tetracycline derivatives Rose bengal sodium (PH-10; Provecta; PV-10; rose bengal; Xantryl) – immunomodulator and other actions Santalum album ointment (albuterpenoid; East Indian sandalwood oil) – undefined mechanism of action Talarozole (R115866; Rambazole) – retinoic acid metabolism modulator Thykamine (PCT-233; PUR-0110) – undefined mechanism of action (anti-inflammatory) Valproic acid topical (Avugane; Baceca; G2M-777) – histone deacetylase inhibitor and other actions XEN-801 (XEN801) – stearoyl-CoA desaturase inhibitor XOMA-629 (XMP-629) – endotoxin inhibitor Zileuton (A-64077; Abbott-64077; ABT-077; CRTX-073; CTI-02; Zyflo) – 5-lipoxygenase inhibitor
Sources: en.wikipedia.org
In advanced cases, bulging of the cornea can result in a localized rupture of Descemet's membrane, an inner layer of the cornea. Aqueous humor from the eye's anterior chamber seeps into the cornea before Descemet's membrane reseals. The patient experiences pain and a sudden severe clouding of vision, with the cornea taking on a translucent milky-white appearance known as a corneal hydrops. Although disconcerting to the patient, the effect is normally temporary and after a period of six to eight weeks, the cornea usually returns to its former transparency. The recovery can be aided nonsurgically by bandaging with an osmotic saline solution. Although a hydrops usually causes increased scarring of the cornea, occasionally it will benefit a patient by creating a flatter cone, aiding the fitting of contact lenses. Corneal transplantation is not usually indicated during corneal hydrops.
HS(CH2)2SH + 2 NR3 + 2 R'I → R'S(CH2)2SR' + 2 [R3NH]I Oxidation of 1,2-ethanedithiol gives a series of oligomers, including the cyclic bis(disulfide). As a 1,2-dithiol, this compound reacts with aldehydes and ketones to give 1,3-dithiolanes, which can be useful intermediates.
=== Epsilon (ε) opioid receptor === Another postulated opioid receptor is the ε opioid receptor. The existence of this receptor was suspected after the endogenous opioid peptide beta-endorphin was shown to produce additional actions that did not seem to be mediated through any of the known opioid receptors. Activation of this receptor produces strong analgesia and release of met-enkephalin; a number of widely used opioid agonists, such as the μ agonist etorphine and the κ agonist bremazocine, have been shown to act as agonists for this effect (even in the presence of antagonists to their more well known targets), while buprenorphine has been shown to act as an epsilon antagonist. Several selective agonists and antagonists are now available for the putative epsilon receptor; however, efforts to locate a gene for this receptor have been unsuccessful, and epsilon-mediated effects were absent in μ/δ/κ "triple knockout" mice, suggesting the epsilon receptor is likely to be either a splice variant derived from alternate post-translational modification, or a heteromer derived from hybridization of two or more of the known opioid receptors.
Sources: en.wikipedia.org
Solid powder is held frozen at -20 °C or below in a desiccated container. Reconstituted solutions are refrigerated and used within a limited period.
Reversed-phase liquid chromatography separates the peptide from related impurities. Mass spectrometry confirms molecular mass, which supports structural identity.
Repeated freezing and thawing can promote aggregation and precipitation of peptide material. Dividing material into single-use aliquots reduces this risk.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.